PDF(Pubmed)
Abstract：
Nodal T-follicular helper cell lymphomas (nTFHLs) represent a new family of peripheral T-cell lymphomas (PTCLs), and comparative studies of their constituents are rare.
This study retrospectively enrolled 10 patients with nTFHL-F and 30 patients with nTFHL-NOS diagnosed between December 2017 and October 2023 at six large comprehensive tertiary hospitals; 188 patients with nTFHL-AI were diagnosed during the same period at the First Affiliated Hospital of Zhengzhou University for comparison.
Compared with nTFHL-AI, nTFHL-NOS patients exhibited better clinical manifestations, lower TFH expression levels, and a lower Ki-67 index. However, no differences in clinicopathological features were observed between nTFHL-F and nTFHL-AI patients as well as nTFHL-NOS patients. According to the survival analysis, the median OS for patients with nTFHL-NOS, nTFHL-AI, and nTFHL-F were 14.2 months, 10 months, and 5 months, respectively, whereas the median TTP were 14 months, 5 months, and 3 months, respectively. Statistical analysis revealed differences in TTP among the three subtypes(P=0.0173). Among the population of patients receiving CHOP-like induction therapy, there were significant differences in the OS and TTP among the nTFHL-NOS, nTFHL-AI, and nTFHL-F patients (P=0.0134, P=0.0205). Both the GDPT and C-PET regimens significantly improved the ORR, OS, and PFS in nTFHL patients.
There are significant differences in the clinical manifestations, pathology, and survival outcomes among the three subtypes of nTFHLs. However, further research with a larger sample size, and involving clinical pathology and molecular genetics is needed to determine the distinctive biological characteristics of these tumors.
This study retrospectively enrolled 10 patients with nTFHL-F and 30 patients with nTFHL-NOS diagnosed between December 2017 and October 2023 at six large comprehensive tertiary hospitals; 188 patients with nTFHL-AI were diagnosed during the same period at the First Affiliated Hospital of Zhengzhou University for comparison.
Compared with nTFHL-AI, nTFHL-NOS patients exhibited better clinical manifestations, lower TFH expression levels, and a lower Ki-67 index. However, no differences in clinicopathological features were observed between nTFHL-F and nTFHL-AI patients as well as nTFHL-NOS patients. According to the survival analysis, the median OS for patients with nTFHL-NOS, nTFHL-AI, and nTFHL-F were 14.2 months, 10 months, and 5 months, respectively, whereas the median TTP were 14 months, 5 months, and 3 months, respectively. Statistical analysis revealed differences in TTP among the three subtypes(P=0.0173). Among the population of patients receiving CHOP-like induction therapy, there were significant differences in the OS and TTP among the nTFHL-NOS, nTFHL-AI, and nTFHL-F patients (P=0.0134, P=0.0205). Both the GDPT and C-PET regimens significantly improved the ORR, OS, and PFS in nTFHL patients.
There are significant differences in the clinical manifestations, pathology, and survival outcomes among the three subtypes of nTFHLs. However, further research with a larger sample size, and involving clinical pathology and molecular genetics is needed to determine the distinctive biological characteristics of these tumors.
摘要：
■淋巴结T滤泡辅助细胞淋巴瘤（nTFHL）代表了外周T细胞淋巴瘤（PTCL）的新家族，对其成分的比较研究很少。
■本研究回顾性纳入2017年12月至2023年10月在6家大型综合性三级医院确诊的10例nTFHL-F患者和30例nTFHL-NOS患者；同期在郑州大学第一附属医院确诊的188例nTFHL-AI患者进行比较。
■与nTFHL-AI相比，nTFHL-NOS患者表现出更好的临床表现，较低的TFH表达水平，和较低的Ki-67指数。然而,nTFHL-F和nTFHL-AI患者以及nTFHL-NOS患者的临床病理特征没有差异。根据生存分析,nTFHL-NOS患者的中位OS，nTFHL-AI,nTFHL-F为14.2个月，10个月,5个月,分别,而中位TTP为14个月，5个月,三个月,分别。统计分析显示三种亚型之间的TTP差异（P=0.0173）。在接受CHOP样诱导治疗的患者人群中，nTFHL-NOS之间的OS和TTP存在显着差异，nTFHL-AI,nTFHL-F患者(P=0.0134,P=0.0205)。GDPT和C-PET方案均显着改善了ORR，操作系统,nTFHL患者的PFS。
■临床表现有显著差异，病理学,nTFHLs三种亚型之间的生存结果。然而,用更大的样本量进行进一步的研究，需要涉及临床病理学和分子遗传学来确定这些肿瘤的独特生物学特征。
■本研究回顾性纳入2017年12月至2023年10月在6家大型综合性三级医院确诊的10例nTFHL-F患者和30例nTFHL-NOS患者；同期在郑州大学第一附属医院确诊的188例nTFHL-AI患者进行比较。
■与nTFHL-AI相比，nTFHL-NOS患者表现出更好的临床表现，较低的TFH表达水平，和较低的Ki-67指数。然而,nTFHL-F和nTFHL-AI患者以及nTFHL-NOS患者的临床病理特征没有差异。根据生存分析,nTFHL-NOS患者的中位OS，nTFHL-AI,nTFHL-F为14.2个月，10个月,5个月,分别,而中位TTP为14个月，5个月,三个月,分别。统计分析显示三种亚型之间的TTP差异（P=0.0173）。在接受CHOP样诱导治疗的患者人群中，nTFHL-NOS之间的OS和TTP存在显着差异，nTFHL-AI,nTFHL-F患者(P=0.0134,P=0.0205)。GDPT和C-PET方案均显着改善了ORR，操作系统,nTFHL患者的PFS。
■临床表现有显著差异，病理学,nTFHLs三种亚型之间的生存结果。然而,用更大的样本量进行进一步的研究，需要涉及临床病理学和分子遗传学来确定这些肿瘤的独特生物学特征。
